Martin Fan
Stock Analyst at Wedbush
(4.71)
# 89
Out of 5,055 analysts
12
Total ratings
66.67%
Success rate
53.87%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Martin Fan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SANA Sana Biotechnology | Maintains: Outperform | $5 → $6 | $3.46 | +73.41% | 2 | Nov 7, 2025 | |
| ARTV Artiva Biotherapeutics | Maintains: Outperform | $18 → $23 | $3.82 | +501.78% | 2 | Oct 17, 2025 | |
| ZBIO Zenas BioPharma | Maintains: Outperform | $35 → $40 | $35.27 | +13.41% | 2 | Oct 9, 2025 | |
| ANAB AnaptysBio | Reiterates: Outperform | $45 | $34.55 | +30.25% | 3 | Sep 30, 2025 | |
| RNAC Cartesian Therapeutics | Initiates: Outperform | $38 | $7.51 | +406.33% | 1 | Jul 9, 2025 | |
| ACRS Aclaris Therapeutics | Initiates: Outperform | $8 | $2.41 | +231.95% | 1 | May 28, 2025 | |
| ORKA Oruka Therapeutics | Reiterates: Outperform | $40 | $27.42 | +45.88% | 1 | May 15, 2025 |
Sana Biotechnology
Nov 7, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $3.46
Upside: +73.41%
Artiva Biotherapeutics
Oct 17, 2025
Maintains: Outperform
Price Target: $18 → $23
Current: $3.82
Upside: +501.78%
Zenas BioPharma
Oct 9, 2025
Maintains: Outperform
Price Target: $35 → $40
Current: $35.27
Upside: +13.41%
AnaptysBio
Sep 30, 2025
Reiterates: Outperform
Price Target: $45
Current: $34.55
Upside: +30.25%
Cartesian Therapeutics
Jul 9, 2025
Initiates: Outperform
Price Target: $38
Current: $7.51
Upside: +406.33%
Aclaris Therapeutics
May 28, 2025
Initiates: Outperform
Price Target: $8
Current: $2.41
Upside: +231.95%
Oruka Therapeutics
May 15, 2025
Reiterates: Outperform
Price Target: $40
Current: $27.42
Upside: +45.88%